Call +41-61-926-60-40 Fax +41-61-926-60-49

YC-1

AG-CR1-0120-M001 1 mg INQ
AG-CR1-0120-M005 5 mg INQ
AG-CR1-0120-M025 25 mg INQ
Actions
Select size:

* Required Fields

Amount:
Add to Cart
Call +41-61-926-60-40
Fax +41-61-926-60-49
Contact Us!

Additional Information

Product Data
Synonyms 3-(5'-Hydroxymethyl-2'-furyl)-1-benzylindazole
Properties
Formula C19H16N2O2
MW 304.4
CAS 170632-47-0
Purity ≥98% (NMR)
Appearance White to pale yellow powder.
Solubility Soluble in DMSO, methanol or dichloromethane.
Identity Determined by 1H-NMR.
InChi Key OQQVFCKUDYMWGV-UHFFFAOYSA-N
Product Type Chemical
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light.
Use/Stability Stable for at least 2 years after receipt when stored at +4°C.
Documents
MSDS Download Document Download

Product Description

  • Nitric oxide (NO) independent, superoxide-sensitive soluble guanylyl cyclase (sGC) activator [1, 4]. 
  • Induces concentration-dependent increase in cGMP levels [1, 4].
  • Inhibits platelet adhesion to collagen [2, 8]. 
  • Thombosis inhibitor [3]. 
  • Non-specific phosphodiesterase inhibitor [5].
  • Na+ channel blocker [6, 9].
  • Anticancer compound [7, 8].
  • HIF-α inhibitor [7, 10].
  • Blocks angiogenesis. Tumor growth inhibitor [7, 10]. 
  • Apoptosis inducer [11].
  • NK cell differentiation enhancer [12].
  • TRAIL sensitizer [13].

Product References

  1. YC-1, a novel activator of platelet guanylate cyclase: F.N. Ko, et al.; Blood 84, 4226 (1994)
  2. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase: C.C. Wu, et al.; Br. J. Pharmacol. 116, 1973 (1995)
  3. YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice: C.M. Teng, et al.; Eur. J. Pharmacol. 320, 161 (1997)
  4. Mechanism of YC-1-induced activation of soluble guanylyl cyclase: A. Friebe & D. Koesling; Mol. Pharmacol. 53, 123 (1998)
  5. BAY 41-2272 activates two isoforms of nitric oxide-sensitive guanylyl cyclase: M. Koglin, et al.; BBRC 292, 1057 (2002)
  6. Soluble guanylyl cyclase activator YC-1 protects white matter axons from nitric oxide toxicity and metabolic stress, probably through Na(+) channel inhibition: G. Garthwaite, et al.; Mol. Pharmacol. 61, 97 (2002)
  7. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1: E.J. Yeo, et al.; J. Natl. Cancer Inst. 95, 516 (2003)
  8. Versatile pharmacological actions of YC-1: anti-platelet to anticancer: Y.S. Chun, et al.; Cancer Lett. 207, 1 (2004) (Review)
  9. A Novel Drug Binding Site on Voltage-Gated Sodium Channels in Rat Brain: D. R. Riddall, et al.; Mol. Pharmacol. 69, 278 (2006)
  10. Preclinical evaluation of YC-1, a HIF inhibitor, for the prevention of tumor spreading: D.H. Shin, et al.; Cancer Lett. 255, 107 (2007)
  11. YC-1 induces apoptosis of human renal carcinoma A498 cells in vitro and in vivo through activation of the JNK pathway: S.Y. Wu, et al.; Br. J. Pharmacol. 155, 505 (2008)
  12. YC-1 enhances natural killer cell differentiation from hematopoietic stem cells: S. Yun, et al.; Int. Immunopharmacol. 10, 481 (2010)
  13. Novel HTS strategy identifies TRAIL-sensitizing compounds acting specifically through the caspase-8 apoptotic axis: D. Finlay, et al.; PLoS One 5, e13375 (2010)
No reviews for this product yet.